Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Pier Giorgio Cojutti

Senior assistant professor

University of Bologna

Italy

This profile is automatically generated from trusted academic sources.

Google Scholar

.

ORCID

.

LinkedIn

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI

Contact this professor

LinkedIn

Google Scholar

Research Interests

Pharmacotherapy

60%

Pharmacology

20%

Antibiotic Therapy

60%

Pharmacokinetic

50%

Critical Care Medicine

30%

Pharmacodynamic

30%

Antibiotic Resistance

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of <i>Staphylococcal osteoarticular</i> Infections?

Year:

2025

Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients

Year:

2022

Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency

Year:

2022

Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases

Year:

2022

Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?"

Year:

2022

Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring

Year:

2022

A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings

Year:

2021

A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol

Year:

2021

Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections

Year:

2021

Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”

Year:

2021

Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization

Year:

2021

Collaborators1

Maddalena Giannella

-

ITALY

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI